Author:
Schuler E,Giagounidis A,Haase D,Shirneshan K,Büsche G,Platzbecker U,Nolte F,Götze K,Schlenk R F,Ganser A,Letsch A,Braulke F,Lübbert M,Bug G,Schafhausen P,Bacher U,Gattermann N,Wulfert M,Haas R,Germing U
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference15 articles.
1. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671–3674.
2. Wulfert M, Kupper AC, Tapprich C, Bottomley SS, Bowen D, Germing U et al. Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol 2008; 36: 577–586.
3. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456–1465.
4. Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011; 118: 3765–3776.
5. Geyh S, Oz S, Cadeddu RP, Frobel J, Bruckner B, Kundgen A et al. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013; 27: 1841–1851.
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献